Research Outcomes

• Development of "dynamic nanomedicines" for efficient delivery of nucleic acid medicines to sentinel lymph nodes.
• Delivering nucleic acid medicines to sentinel lymph nodes, which serve as a checkpoint for cancer metastasis, activates the immune system, helping to suppress cancer metastasis and recurrence.
• Enhancing cancer immunotherapy to make it effective against immunotherapy-resistant tumors.
• Precise size adjustment of nanomedicines (approximately 10 nm) enables delivery to sentinel lymph nodes.
• Precision nanomedicine design via advanced computational modelling.
• Aim to start clinical trials within five years.
• This announcement is part of a research project conducted by Professor Kanjiro Miyata of the Graduate School of Engineering, The University of Tokyo (Visiting Research Scientist at iCONM), in collaboration with iCONM researchers.

https://www.eurekalert.org/news-releases/1088427